Skip to main content

Year: 2025

PRESS RELEASE DATED 12 DECEMBER 2025 REGARDING THE IMPLEMENTATION OF THE SQUEEZE-OUT OF TARKETT

  PRESS RELEASE DATED 12 DECEMBER 2025 REGARDING THE IMPLEMENTATION OF THE SQUEEZE-OUT OF TARKETT FOLLOWING THE PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT INITIATED BY TARKETT PARTICIPATION  AMOUNT OF INDEMNIFICATION:€17 per Tarkett ordinary share AUTORITE DES MARCHES FINANCIERS   This press release has been prepared by Tarkett Participation and distributed in accordance with the provisions of Article 237-3 III of the General Regulations of the Autorité des marchés financiers (the “AMF”) and Article 9 of AMF Instruction No. 2006-07 relating to takeover bids, as amended.Target company: Tarkett, a société anonyme with a supervisory board and management board, whose registered office is located at Tour Initiale – 1, Terrasse Bellini, 92919 Paris La Défense Cedex, registered with the Nanterre Trade and Companies Register...

Continue reading

New member of the Executive Management of Netcompany Group A/S

Company announcement No. 43/2025                                               12 December 2025 New member of the Executive Management of Netcompany Group A/S Netcompany Group A/S (“Netcompany”) is expanding its Executive Management with a Chief Commercial Officer (“CCO”) to accelerate European commercialisation. Alexandros Manos will assume the role of CCO and join the Executive Management of Netcompany with effect from 1 January 2026. Since 2021, when Netcompany acquired Intrasoft International S.A. (“Intrasoft”), Alexandros Manos has been the CEO of Netcompany SEE & EUI. As CCO, Alexandros Manos will lead Netcompany’s commercial agenda across all our markets except from Denmark with the aim of accelerating international growth. “I am thrilled to announce the appointment of Alexandros Manos as our new Chief Commercial Officer....

Continue reading

EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint

EssilorLuxottica to acquire Signifeye,further growing its ophthalmology clinics footprint Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and clinics in the Flanders region. The transaction comes soon after the recent acquisition of Optegra, a fast-growing and highly integrated ophthalmology platform in Europe operating over 70 clinics in the UK, Czech Republic, Poland, Slovakia and the Netherlands. While strengthening Optegra’s position in Europe, it also advances EssilorLuxottica’s med-tech trajectory and its ambition to pioneer the most advanced, integrated and expert-driven medical model, capable of addressing the full continuum of need, from prevention and early detection to specialized...

Continue reading

Ensurge Micropower ASA – Reminder of last day of subscription period in the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.  Oslo, Norway, 12 December 2025  Reference is made to the stock exchange notice from Ensurge Micropower ASA (the “Company”) on 5 December 2025 regarding the commencement of subscription period (the “Subscription Period”) in the subsequent offering (the “Subsequent Offering”) consisting of up to 22,222,222 new shares at a subscription price of NOK 0.90 per share (“Offer Shares”).  The Subscription Period will end today, 12 December 2025, at 16:30 CET.  This Subsequent Offering...

Continue reading

IMCD: Supervisory Board members nominated for reappointment

Rotterdam, The Netherlands (12 December 2025) – “IMCD N.V. (“IMCD” or “Company”), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, announces that the Supervisory Board of IMCD nominates Mr. Janus Smalbraak for reappointment as member and Chair of the Supervisory Board at the next Annual General Meeting (AGM) in 2026. In addition to the nomination of Janus Smalbraak, the Supervisory Board nominates Mr. Stephan Nanninga for a third term of two years and Mr. Willem Eelman for a second term of four years on the Supervisory Board of IMCD. Janus Smalbraak was first appointed in 2016 and reappointed in 2020 and 2024. He currently serves as Chair of the Supervisory Board and Chair of the Nomination & Appointment Committee. The Supervisory Board now nominates him...

Continue reading

Elis: Disclosure of trading in own shares occured from December 8 to December 10, 2025

Disclosure of trading in own shares occurred from December 8 to December 10, 2025 Puteaux, December 12, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from December 8 to December 10, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders’ Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation:Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code)ELIS SA 969500UX71LCE8MAY492 12/08/2025 FR0012435121 19,483 23.5911 XPARELIS SA 969500UX71LCE8MAY492 12/08/2025 FR0012435121 5,051 23.5943 CEUXELIS SA 969500UX71LCE8MAY492 12/08/2025 FR0012435121 674 23.6042 TQEXELIS...

Continue reading

WENDEL: Wendel Investor Day

Wendel’s transformation: two powerful value creation engines expected to generate more than €7 billion in cash flow by end 2030 and to return at least €1.6 billion to shareholders  Cancellation of 3.8% of treasury shares and launch of a share buyback representing 9% of the share capital in 2026 In less than three years, Wendel has carried out a major strategic transformation, evolving from a traditional investment holding company into a global investment firm focused on creating value through controlled private assets, serving both its clients and shareholders, while preserving its long-term investor DNA. By the end of 2030, the accelerated development of third-party asset management (WIM) and the active management of principal investments (WPI) will support an attractive shareholder return policy, with more than €1.6 billion in...

Continue reading

BW Energy: Strategic entry offshore Angola through acquisition of 10% in Block 14 and 5% in Block 14k

BW Energy has in a consortium with Maurel & Prom signed an agreement to acquire a combined 20% non-operated interest in Block 14 and 10% in Block 14K offshore Angola from Azule Energy. Within this transaction, BW Energy’s net share will be 10% in Block 14 and 5% in Block 14K, providing a strategic foothold in Angola aligned with the Company’s long-term regional growth strategy. “The entry to Angola is a key step in BW Energy’s West Africa growth strategy and provides further diversification of our resource base. Firstly, we see clear upsides beyond the current production in Block 14. And, more importantly, we build a position for potential future operated development opportunities in the country,” said Carl K. Arnet, the CEO of BW Energy. “Angola is a mature hydrocarbon basin with an active M&A market and strong political support...

Continue reading

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company AnnouncementTransaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained growth into the next decade and contributing to...

Continue reading

Ascot Announces Share Consolidation Effective Date

VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSXV: AOT.H; OTCID: AOTVF) (“Ascot” or the “Company”) announces that the effective date for the previously announced share consolidation (the “Consolidation”) will be December 16, 2025. As outlined in the Company’s news release dated October 23, 2025, the Consolidation will be conducted on the basis of (50) pre-consolidation common shares (the “Pre-Consolidation Shares”) for one (1) post-consolidation common share (the “Post-Consolidation Shares”). The Consolidation is part of a larger restructuring process, including a rights offering, the Consolidation, a bridge financing and a private placement. The Post-Consolidation Shares are scheduled to begin trading on NEX Board (the “NEX”) of the TSX Venture Exchange (the “TSX-V”) at the market open on...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.